An important ruling of the Court of Justice of the European
Union (CJEU) on 3 September 2024, in two cases brought by Illumina
and Grail against the European Commission (EC), has essentially
held that a company's right to legal certainty places a limit
on the EC's most flexible merger control powers. The relevant
powers, under Art. 22 of the EU Merger Regulation (EUMR), have been
invoked over the last 3 years at the 'new frontiers' of EU
enforcement against suspected 'killer acquisitions' of
companies which do not meet merger control turnover thresholds.
This is a valuable CJEU ruling for companies engaged in M&A
in the EU. It may however result in the Irish Competition Authority
(CCPC) having a bigger role in global merger control and
specifically in helping the EC review suspected 'killer
acquisitions' involving Irish-based pharma and tech companies
in particular. We explain why below-